Chapter 18 Strategies in the development of peptide antagonists
- 1 January 1992
- book chapter
- Published by Elsevier
- Vol. 92, 215-224
- https://doi.org/10.1016/s0079-6123(08)61177-2
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Synthetic glucagon antagonists and partial agonistsInternational Journal of Peptide and Protein Research, 1991
- Conformationally restricted analogs of oxytocin; stabilization of inhibitory conformation†International Journal of Peptide and Protein Research, 1990
- Conformational and Structural Considerations in Oxytocin-Receptor Binding and Biological ActivityAnnual Review of Pharmacology and Toxicology, 1990
- Bicyclization of a weak oxytocin agonist produces a highly potent oxytocin antagonistJournal of the American Chemical Society, 1990
- Importance of the C‐terminal α‐helical structure for glucagon's biological activityInternational Journal of Peptide and Protein Research, 1988
- Design and synthesis of somatostatin analogs with topographical properties that lead to highly potent and specific .mu. opioid receptor antagonists with greatly reduced binding at somatostatin receptorsJournal of Medicinal Chemistry, 1988
- Conformation of d‐Phe‐Cys‐Tyr‐d‐Trp‐Lys‐Thr‐Pen‐Thr‐NH2 (CTP‐NH2), a highly selective mu‐opioid antagonist peptide, by 1H and 13C n.m.r.International Journal of Peptide and Protein Research, 1988
- Implications of the X-ray structure of deamino-oxytocin to agonist/antagonist-receptor interactionsTrends in Pharmacological Sciences, 1987
- Design and synthesis of conformationally constrained somatostatin analogs with high potency and specificity for .mu. opioid receptorsJournal of Medicinal Chemistry, 1986
- Conformational considerations in the design of a glucagon analog with increased receptor binding and adenylate cyclase potenciesJournal of the American Chemical Society, 1986